Elypta, the Swedish company pioneering metabolism-based early cancer detection, is pleased to announce the appointment of Dr. Hilja Ibert to its Board of Directors. Hilja brings extensive leadership experience in the diagnostics industry and a strong track record of commercial success.
“Hilja’s deep expertise in commercializing diagnostics will be invaluable as we aim to launch our first diagnostic products next year,” says Elypta CEO Karl Bergman.
Dr. Ibert has over 30 years of experience in clinical diagnostics, having held senior positions at international companies, including Hologic, Becton Dickinson, and bioMérieux. She recently served as CEO and now chairs the Board of Gentian Diagnostics ASA, where she played a key role in the company’s growth and success. She is also a board member at Gradientech, a company specializing in ultra-rapid antibiotic susceptibility testing, and VitaDx, a pioneer in AI and image processing in the field of cytology for cancer diagnostics.
Dr. Ibert holds a Ph.D. in Microbiology and a degree in Nutritional Sciences from the Rheinische Friedrich Wilhelms Universität of Bonn, Germany.
“I am excited to join Elypta at this pivotal moment as the company prepares to bring its diagnostic solutions to market, and I look forward to contributing to Elypta’s commercial success,” says Dr. Ibert.
“Hilja’s wealth of experience in commercializing diagnostics will be instrumental in ensuring maximal impact of Elypta’s technology and advancing our mission to prevent cancer mortality through early detection,” says Elypta chairman and founder, Jens Nielsen.
For more information, please contact:
Karl Bergman,CEO, info@elypta.com
About Elypta
Elypta is a Swedish cancer detectioncompany focused on reducing cancer mortality by enabling earlier detection andcloser monitoring. The metabolism-based liquid biopsy platform measures a novelpanel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detectcancer-specific signatures. Elypta is advancing a broad study program acrossdifferent cancers with the leading indications being early detection ofrecurrence in renal cell carcinoma and multi-cancer early detection.www.elypta.com
